Milena Bastos Brito

Research Field

The National Family Planning Policy was created in Brazil in 2007. It includes offering eight free contraceptive methods (intrauterine device [IUD] with copper, progestogen-only pill, combined pill, monthly injectable, depot medroxyprogesterone, diaphragm, male and female condoms) and also some other oral and injectable contraceptives at reduced prices at "popular" pharmacies. In the last decades, modern contraceptive methods have been developed, such as levonorgestrel intrauterine system (IUS) and subdermal implants, but these are not accessible to the majority of the Brazilian population because they are not available (for free or at a low cost) in the national health system.[1]

Pill

Levonorgestrel

10.1055/s-0036-1593411

Cite

Citations (7)

Neovaginoplastia com molde de látex natural: uma nova proposta terapêutica

Luiz Gustavo Oliveira Brito Bruno Ramalho de Carvalho Milena Bastos Brito Ionara Diniz Evangelista Sousa Barcelos Antônio Alberto Nogueira

Source

Cite

Citations (0)

Use of etonogestrel-releasing contraceptive implant in the immediate post partum period

Fertility and Sterility (2008)

Milena Bastos Brito Rui Alberto Ferriani Marcos Felipe Silva de Sá Silvana Maria Quintana Carolina Sales Vieira

Etonogestrel

Contraceptive implant

10.1016/j.fertnstert.2008.07.1336

Cite

Citations (0)

Effect of the levonorgestrel‐releasing intrauterine system on cardiovascular risk markers among women with thrombophilia or previous venous thromboembolism

International Journal of Gynecology & Obstetrics (2019)

Giordana Campos Braga Milena Bastos Brito Rui Alberto Ferriani Luciana Coutinho de Oliveira Andréa A. Garcia

10.1002/ijgo.13070

Cite

Citations (5)

Medical Residency in Gynecology and Obstetrics in Times of COVID-19: Recommendations of the National Specialized Commission on Medical Residency of FEBRASGO

Revista Brasileira Ginecologia e Obstetrícia (2020)

Gustavo Salata Romão Lucas Schreiner Cláudia Lourdes Soares Laranjeira Zsuzsanna Ilona Katalin de Jármy Di Bella Raquel Autran Coelho Peixoto

The COVID-19 pandemic (Coronavirus Disease 2019) has affected residencies training around the world. In the light of responses to the pandemic, many medical residencies are being forced to reorganize their rotations. These changes include a reduction in the operating room and outpatient care training, and the cancellation of some activities such as visits to the wards, simulation sessions, among others.[1]

Pandemic

Graduate medical education

2019-20 coronavirus outbreak

10.1055/s-0040-1715147

Cite

Citations (11)

Blue Light-Emitting Diode Therapy for Chronic Vulvovaginitis Symptoms: A Series of Cases

Photobiomodulation Photomedicine and Laser Surgery (2022)

Ana Cláudia Machado Pereira e Silva Milena Bastos Brito Mariana Robatto Maria Clara Pavie Andrea Q. Villas Boas

Objective: This pilot study aimed to evaluate the characteristic signs and symptoms of chronic vulvovaginitis after blue light-emitting diode (LED) treatment. Methods: Women with characteristic signs and symptoms of vulvovaginitis were interviewed to obtain clinical and sociodemographic data. They answered the Female Sexual Function Index (FSFI) and the World Health Organization Quality of Life (WHOQOL)-bref questionnaires. Women with a suspected diagnosis of vulvovaginitis underwent clinical examination by a gynecologist, followed by microbiological evaluation, potassium hydroxide testing, vaginal pH assessment, and collection of vaginal fluid for oncotic cytology and fungal culture. The study participants were instructed to return after 15 days to undergo the 405 nm blue LED treatment, which consisted of three biweekly sessions. After 28 days of treatment completion, the patients returned for clinical re-evaluation and reassessment of the FSFI and WHOQOL-bref scores. Results: All eight women reported improvement or cure of at least one characteristic sign or symptom of vulvovaginitis, and five showed improvement in total FSFI and WHOQOL-bref scores. Conclusions: Treatment with blue LED may improve or cure symptoms associated with vulvovaginitis, sexual function, and the global quality of life score. Clinical Trial registration: NCT03075046 dated March 9, 2017.

Vaginal discharge

10.1089/photob.2022.0038

Cite

Citations (5)

O148 Metabolic effects of the etonogestrel‐releasing implant during the immediate postpartum period

International Journal of Gynecology & Obstetrics (2009)

Milena Bastos Brito Rui Alberto Ferriani Salvador Quintana M. Silva De Sá C. A Vieira

Etonogestrel

10.1016/s0020-7292(09)60520-8

Cite

Citations (0)

O146 Medical treatment of tubal ectopic pregnancy - How far can we go with methotrexate's use?